MannKind Corporation
MNKD
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.3B
$4.06
▲ +2.53%
P/E
-29.57
Mkt Cap
$1.3B
52-Wk Range
$2.23–$6.51
52-Week Range
$2.23 - $6.51
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 27.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary inhaled drug delivery technology platform
- First-mover advantage in FDA-approved inhaled insulin market
- Strategic partnerships with established pharmaceutical companies
- Diversified pipeline addressing multiple therapeutic areas with limited competition
Bear Case
1 risk
- Average volatility.
Growth
Moderate growth ahead
Expanding Afrezza market adoption among diabetes patients seeking insulin alternatives
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Strong
+19.8% over 3m
Quality
Excellent
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying MNKD right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
AUG 5, 2026
Reported EPS of -$0.06 vs -$0.01 consensus (-700.0% surprise). Revenue of $109.4M vs $108.1M expected (+1.2%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-700.0%
Revenue trend · last 8Q
—
+31%
+18%
+6%
+17%
+46%
+15%
+43%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$70.1M
$76.8M
$78.4M
$76.5M
$82.1M
$112.0M
$90.2M
$109.4M
Margins · last 8Q
Gross
86.2%
Operating
-0.3%
Profit
-17.4%
Wall Street consensus
4 analysts · 75% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
75%
Hold
25%
Sell
0%
Median Price Target
—
Latest: Wells Fargo · Jul 30, 2026
vs Industry
How MNKD stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related